Published in J Clin Oncol on August 11, 2014
Radiation oncology in the era of precision medicine. Nat Rev Cancer (2016) 0.97
Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations. Transl Oncol (2016) 0.77
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. Clin Cancer Res (2016) 0.75
Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. Br J Radiol (2015) 0.75
The changing paradigm of tumour response to irradiation. Br J Radiol (2016) 0.75
Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov (2011) 22.33
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Epigenetic reprogramming in cancer. Science (2013) 3.47
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys (2014) 2.28
NIH mulls rules for validating key results. Nature (2013) 1.97
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol (2012) 1.43
Radiation induced non-targeted response: mechanism and potential clinical implications. Curr Mol Pharmacol (2011) 1.36
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
Radiation as an immune modulator. Semin Radiat Oncol (2013) 1.19
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res (2014) 1.13
Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One (2010) 1.13
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer (2011) 1.08
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol (2014) 1.05
Structural Implications for Selective Targeting of PARPs. Front Oncol (2013) 1.04
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys (2014) 1.03
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol (2011) 1.02
Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol Cancer Res (2012) 1.02
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther (2013) 1.01
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
Molecular radiobiology: the state of the art. J Clin Oncol (2014) 0.96
Spatially fractionated radiation induces cytotoxicity and changes in gene expression in bystander and radiation adjacent murine carcinoma cells. Radiat Res (2012) 0.96
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst (2012) 0.94
Direct comparison of biologically optimized spread-out bragg peaks for protons and carbon ions. Int J Radiat Oncol Biol Phys (2007) 0.89
Lessons learned from radiation oncology clinical trials. Clin Cancer Res (2013) 0.89
Developing precision medicine in a global world. Clin Cancer Res (2014) 0.87
Nanotechnology in radiation oncology. J Clin Oncol (2014) 0.86
Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res (2013) 0.84
Using genetically engineered mice for radiation research. Radiat Res (2011) 0.84
Milestones in the use of combined-modality radiation therapy and chemotherapy. J Clin Oncol (2014) 0.80
An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am (2013) 0.78